| Nome |
# |
|
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis, file e398c378-c01d-179a-e053-3705fe0a4cff
|
1.009
|
|
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study., file e398c379-e006-179a-e053-3705fe0a4cff
|
752
|
|
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele., file e398c378-a5d8-179a-e053-3705fe0a4cff
|
621
|
|
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment., file e398c378-a7e4-179a-e053-3705fe0a4cff
|
529
|
|
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis., file e398c379-e06b-179a-e053-3705fe0a4cff
|
481
|
|
Current management strategies for polycythemia vera and essential thrombocythemia, file e398c381-a02d-179a-e053-3705fe0a4cff
|
464
|
|
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment., file e398c37b-a2ca-179a-e053-3705fe0a4cff
|
457
|
|
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)., file e398c37b-a620-179a-e053-3705fe0a4cff
|
454
|
|
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN, file e398c378-a271-179a-e053-3705fe0a4cff
|
449
|
|
Clinical significance of genetic aberrations in secondary acute myeloid leukemia, file e398c378-d7a1-179a-e053-3705fe0a4cff
|
291
|
|
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation, file e398c37b-a050-179a-e053-3705fe0a4cff
|
288
|
|
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia., file e398c37b-a0bd-179a-e053-3705fe0a4cff
|
284
|
|
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia., file e398c37b-a0ce-179a-e053-3705fe0a4cff
|
273
|
|
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis, file e398c379-988a-179a-e053-3705fe0a4cff
|
248
|
|
Advances in understanding and management of myeloproliferative neoplasms, file e398c378-a34b-179a-e053-3705fe0a4cff
|
223
|
|
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis, file e398c379-9be6-179a-e053-3705fe0a4cff
|
216
|
|
Effect of mutation order on myeloproliferative neoplasms, file e398c379-99da-179a-e053-3705fe0a4cff
|
210
|
|
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia, file e398c37b-a852-179a-e053-3705fe0a4cff
|
209
|
|
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction., file e398c378-a7e5-179a-e053-3705fe0a4cff
|
205
|
|
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis, file e398c37c-930f-179a-e053-3705fe0a4cff
|
189
|
|
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis., file e398c37b-9db7-179a-e053-3705fe0a4cff
|
185
|
|
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone, file e398c378-d7a2-179a-e053-3705fe0a4cff
|
169
|
|
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance., file e398c37b-a16a-179a-e053-3705fe0a4cff
|
169
|
|
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms., file e398c378-b6c7-179a-e053-3705fe0a4cff
|
166
|
|
Targeted deep sequencing in polycythemia vera and essential thrombocythemia, file e398c37e-84a3-179a-e053-3705fe0a4cff
|
161
|
|
EZH2 mutational status predicts poor survival in myelofibrosis., file e398c37a-bf37-179a-e053-3705fe0a4cff
|
152
|
|
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia., file e398c37b-a688-179a-e053-3705fe0a4cff
|
148
|
|
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial, file e398c379-9e7b-179a-e053-3705fe0a4cff
|
144
|
|
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients, file e398c37b-9839-179a-e053-3705fe0a4cff
|
144
|
|
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2., file e398c37a-43a4-179a-e053-3705fe0a4cff
|
142
|
|
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis, file e398c37b-98d7-179a-e053-3705fe0a4cff
|
142
|
|
HDAC1 controls CIP2A transcription in human colorectal cancer cells, file e398c37a-6f22-179a-e053-3705fe0a4cff
|
141
|
|
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia., file e398c37b-a762-179a-e053-3705fe0a4cff
|
141
|
|
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells, file e398c37b-98d8-179a-e053-3705fe0a4cff
|
140
|
|
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis., file e398c378-ced2-179a-e053-3705fe0a4cff
|
136
|
|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium, file e398c37b-a0cb-179a-e053-3705fe0a4cff
|
135
|
|
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis, file e398c379-9b01-179a-e053-3705fe0a4cff
|
134
|
|
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs., file e398c378-dd98-179a-e053-3705fe0a4cff
|
133
|
|
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues., file e398c378-a5e1-179a-e053-3705fe0a4cff
|
129
|
|
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms, file e398c379-9abf-179a-e053-3705fe0a4cff
|
128
|
|
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis, file e398c379-9f82-179a-e053-3705fe0a4cff
|
125
|
|
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086, file e398c378-95cd-179a-e053-3705fe0a4cff
|
124
|
|
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis, file e398c37e-0af0-179a-e053-3705fe0a4cff
|
122
|
|
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet., file e398c378-ced1-179a-e053-3705fe0a4cff
|
121
|
|
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition., file e398c378-b001-179a-e053-3705fe0a4cff
|
120
|
|
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing, file e398c37d-86c2-179a-e053-3705fe0a4cff
|
120
|
|
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer, file e398c37f-2e49-179a-e053-3705fe0a4cff
|
120
|
|
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms., file e398c37b-a0cf-179a-e053-3705fe0a4cff
|
119
|
|
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells, file e398c379-9c30-179a-e053-3705fe0a4cff
|
113
|
|
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants, file e398c37e-e4a3-179a-e053-3705fe0a4cff
|
113
|
|
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis, file e398c37e-a2ed-179a-e053-3705fe0a4cff
|
111
|
|
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives, file e398c378-a5db-179a-e053-3705fe0a4cff
|
110
|
|
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms., file e398c37a-54a5-179a-e053-3705fe0a4cff
|
107
|
|
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study, file e398c379-9e75-179a-e053-3705fe0a4cff
|
105
|
|
Cardiovascular events and intensity of treatment in polycythemia vera., file e398c379-e089-179a-e053-3705fe0a4cff
|
104
|
|
Circ RNAs are here to stay: A perspective on the MLL recombinome, file e398c37e-de1e-179a-e053-3705fe0a4cff
|
103
|
|
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera., file e398c37b-a7dc-179a-e053-3705fe0a4cff
|
102
|
|
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, file e398c37b-a1ba-179a-e053-3705fe0a4cff
|
101
|
|
Chronic myeloproliferative neoplasms: a collaborative approach., file e398c37b-6122-179a-e053-3705fe0a4cff
|
100
|
|
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms, file e398c37b-9338-179a-e053-3705fe0a4cff
|
97
|
|
The european hematology association roadmap for european hematology research: A consensus document, file e398c37b-d755-179a-e053-3705fe0a4cff
|
92
|
|
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis, file e398c37b-91f0-179a-e053-3705fe0a4cff
|
89
|
|
Diagnostic and therapeutic challenges in mast cell sarcoma, file cbe32a33-74e8-4eb3-af28-c662b44ac259
|
85
|
|
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6, file e398c37b-cf2c-179a-e053-3705fe0a4cff
|
83
|
|
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial, file e398c37b-d66b-179a-e053-3705fe0a4cff
|
77
|
|
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis, file e398c37c-e9e8-179a-e053-3705fe0a4cff
|
75
|
|
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients, file e398c37e-e6c1-179a-e053-3705fe0a4cff
|
75
|
|
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis, file e398c37e-c9de-179a-e053-3705fe0a4cff
|
74
|
|
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group, file e398c37b-d846-179a-e053-3705fe0a4cff
|
69
|
|
STAT1 activation in association with JAK2 exon 12 mutations, file e398c37b-a1b6-179a-e053-3705fe0a4cff
|
64
|
|
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials, file e398c37b-d3db-179a-e053-3705fe0a4cff
|
64
|
|
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells, file e398c378-c3f0-179a-e053-3705fe0a4cff
|
61
|
|
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms, file e398c37b-98a2-179a-e053-3705fe0a4cff
|
60
|
|
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis, file e398c37e-de16-179a-e053-3705fe0a4cff
|
50
|
|
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis., file e398c37b-9d50-179a-e053-3705fe0a4cff
|
49
|
|
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis., file e398c378-a7e7-179a-e053-3705fe0a4cff
|
43
|
|
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet, file e398c37e-e390-179a-e053-3705fe0a4cff
|
31
|
|
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis, file e398c37b-dd02-179a-e053-3705fe0a4cff
|
27
|
|
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis., file e398c37a-4dc4-179a-e053-3705fe0a4cff
|
23
|
|
Myeloid sarcoma: more and less than a distinct entity, file cb658963-602f-41b9-9ac6-72e65c596e82
|
22
|
|
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion, file e398c37c-b86a-179a-e053-3705fe0a4cff
|
20
|
|
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study, file e398c382-3e4c-179a-e053-3705fe0a4cff
|
19
|
|
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis., file e398c379-d6d4-179a-e053-3705fe0a4cff
|
12
|
|
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project, file 9ab2c970-d6dd-4f57-8c91-249fb92ba35a
|
11
|
|
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia, file c30040df-9dcb-4220-b883-e7f7f04db448
|
11
|
|
Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities?, file 04513aee-09f4-47a2-97e7-921da4650377
|
9
|
|
Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques, file 3611489b-0a04-497c-b78f-af3c3027dfa2
|
9
|
|
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020, file 93f911a2-8267-4af2-beef-a2a79146638d
|
7
|
|
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis, file e398c381-ec2a-179a-e053-3705fe0a4cff
|
4
|
|
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data, file e398c37e-de20-179a-e053-3705fe0a4cff
|
3
|
|
WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential, file e398c378-976e-179a-e053-3705fe0a4cff
|
2
|
|
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis., file e398c37a-0a58-179a-e053-3705fe0a4cff
|
2
|
|
Rationale for combination therapies in myelofibrosis, file e398c37b-9ae6-179a-e053-3705fe0a4cff
|
2
|
|
MR imaging in non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis, file e398c37b-dc90-179a-e053-3705fe0a4cff
|
2
|
|
MIPSS701 version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis, file e398c37e-de0c-179a-e053-3705fe0a4cff
|
2
|
|
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia, file e398c37f-9f5c-179a-e053-3705fe0a4cff
|
2
|
|
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value., file e398c379-e459-179a-e053-3705fe0a4cff
|
1
|
|
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients, file e398c37b-98a3-179a-e053-3705fe0a4cff
|
1
|
|
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation, file e398c37b-98a4-179a-e053-3705fe0a4cff
|
1
|
|
Struggling with myelofibrosis-associated anemia., file e398c37b-9bed-179a-e053-3705fe0a4cff
|
1
|
| Totale |
14.362 |